Led by Professor Nick Thatcher
Lung cancer is the most common cause of death due to cancer worldwide. In addition to research in treatment of lung cancer, the group is active in strategies to reduce tobacco consumption and prevent the disease.
Most recent research has focused on the development of novel targeted therapies for treatment of lung cancer, particularly epidermal growth factor receptor inhibitors. Phase I studies of these agents are led by Dr Malcolm Ranson, Clinical and Experimental Pharmacology, who works in close conjunction with the lung group.
The international, randomised phase III trial of gefitinib compared to placebo was led by Professor Thatcher and published in the Lancet last year.
Molecular biology of cancer
It is an exciting time in cancer research, with the emergence of multiple targeted therapies for evaluation alone or in combination with conventional chemotherapy and radiotherapy. There is increasing focus on improving knowledge of the molecular biology of cancer, and treatment selection based on molecular characteristics.
The lung group also includes Dr Paul Lorigan and Dr Fiona Blackhall and Dr Corinne Faivre-Finn from the Christie Hospital NHS Trust who are developing clinical trials of novel drug and radiotherapy regimens and building strong links with researchers at the Paterson Institute to expedite the translation of molecular medicine relevant to lung cancer to the clinic.
|Name||Job title||Email address|
|Nick Thatcher||Professor in Medical Oncologyemail@example.com|
|Malcolm Ranson||Senior Lecturer/Honorary Consultant in Oncologyfirstname.lastname@example.org|
|Paul Lorigan||Senior Lecturer in Medical Oncologyemail@example.com|
|Corinne Faivre-Finn||Honorary Lecturerfirstname.lastname@example.org|